These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Kane JM, Yang R, Youakim JM. Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084 [Abstract] [Full Text] [Related]
6. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S. J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406 [Abstract] [Full Text] [Related]
10. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S. Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188 [Abstract] [Full Text] [Related]
11. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R. Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193 [Abstract] [Full Text] [Related]
13. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I. Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786 [Abstract] [Full Text] [Related]